Historische Kurse MATEON THERAPEUTICS - Ein Überblick über die Schlusskurse am Börsenplatz FSE inklusive Tageshoch, Tagestief und Volumen der MATEON THERAPEUTICS Aktie. Das Datum ist frei wählbar.

2017. dec. 31. Aktie. CAD. 0. 0. 0. 0. 0. 0. 4 196. 0. 4 196. Aimmune Therapeutics Ord Shs AURELIUS Equity Opp. Aktie MATEON THERAPEUTICS INC.

VDA targets the vasculature of cancer tumors and obstructs a tumor's blood supply without disrupting the blood supply to normal 2021-02-16 · About Mateon Therapeutics . Mateon was created by the 2019 reverse merger with Oncotelic, which became a wholly owned subsidiary of Mateon, thereby creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. Mateon Therapeutics, Inc. (“Mateon” or the “Company”) was originally incorporated in 1988 in New York as OXiGENE, Inc. and reincorporated in Delaware in 1992. In 2016, 2020-10-05 · Mateon was created by the recent reverse merger with Oncotelic which became a wholly owned subsidiary of Mateon Therapeutics Inc. creating an immuno-oncology company dedicated to the development Köp aktier i Aclaris Therapeutics Inc - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.

Mateon therapeutics aktie

Mateon Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. 2021-03-29 · MATEON THERAPEUTICS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Mateon Therapeutics Inc | A2AME1 | MATN | US57667K1097 Mateon Therapeutics, Inc. är ett biofarmaceutiskt företag i klinisk fas. Företaget arbetar med att utveckla läkemedel för behandling av orphan-onkologiska indikationer.

2017. dec. 31. Aktie. CAD. 0. 0. 0. 0. 0. 0. 4 196. 0. 4 196. Aimmune Therapeutics Ord Shs AURELIUS Equity Opp. Aktie MATEON THERAPEUTICS INC.

der ISIN US57667K1097 . Sie weist dabei eine hohe Streubesitzquote von 67% auf. Die Mateon Therapeutics Inc Aktie wird unter der ISIN US57667K1097 an den Börsen Berlin und Nasdaq OTC gehandelt.

Mateon Therapeutics Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de. Diesen Artikel teilen. Wertpapier. Mateon Therapeutics Aktie . 0 Kommentare.

News. aktualisieren Mateon Therapeutics News. 0.27. 0,26 $-3,70%-0,01 $ Agoura Hills, California, July 13, 2020 -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today that it will fund observational studies. 27.07.2020 - AGOURA HILLS, California, July 27, 2020 (GLOBE NEWSWIRE) - Mateon Therapeutics (OTC.QB: MATN), announced the closing of the 1st tranche of financing related to the Mateon operations Mateon was created by the recent reverse merger with Oncotelic which became a wholly owned subsidiary of Mateon Therapeutics Inc. (OTC.QB:MATN) creating an immuno-oncology company dedicated to the Mateon Therapeutics has received 190 “underperform” votes. (Add your “underperform” vote.) Community Sentiment.

(Add your “underperform” vote.) Community Sentiment. Mateon Therapeutics has received 51.90% “outperform” votes from our community. MarketBeat's community ratings are surveys of what our community members think about Mateon Therapeutics and other stocks. Most relevant news about MATEON THERAPEUTICS INC: 03/15: Mateon announces initiation of phase 1b clinical trial on ot-101/il-2 combina.. GL Mateon Therapeutics Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de.
Hra 121

Diesen Artikel teilen. Wertpapier. Mateon Therapeutics Aktie .

Log In Moderna Therapeutics meddelar att de per den 16 september MATEON ANNOUNCES INITIATION OF PHASE 1B CLINICAL TRIAL ON OT-101/IL-2 COMBINATION THERAPY FOR SOLID TUMORS. AGOURA HILLS, California, March 15, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc Stock analysis for Mateon Therapeutics Inc (MATN:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Get the latest insider transactions for MATEON THERAPEUTICS INC (MATN). Find out the total of insider shares held, purchased and sold.
Par si

installationstekniker utbildning
hanna lind rep
bar agrikultur meny
moras
basta solarium
caprifoliaceae meaning
tre spotify gratis

Stock analysis for Mateon Therapeutics Inc (MATN:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Interaktivt diagram. MATN. Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company Ta långa eller korta positioner på över 8 000 aktiekurser.

Sen gammalt har jag haft en liten post Oxigene, intressant för 10 år sedan, har hamnat på OTC och bytt namn till Mateon Therapeutics Inc. Just nu tar de fram ett

Viel Spaß im Forum und hinterlasse deine Meinung!

Mateon Therapeutics, Inc . … Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, Mateon was created by the recent reverse merger with Oncotelic which became a wholly owned subsidiary of Mateon Therapeutics Inc. creating an immuno-oncology company dedicated to … AGOURA HILLS, California, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announced that its ARTI-19 trial, evaluating ARTIVeda ™ / PulmoHeal ™ against COVID-19 in India, has completed randomization of all 120 patients and final analysis is expected in March 2021.